Status:
ACTIVE_NOT_RECRUITING
Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Bacteriemia
Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
Eligibility:
All Genders
Brief Summary
Background Methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia is a common and serious infection, associated with significant morbidity and high mortality rates. Antistaphylococcal penici...
Detailed Description
Staphylococcus aureus (SA) is a frequent cause of bacteraemia and is associated with high mortality rates. Several studies have reported an increasing incidence over recent decades, accompanied by a d...
Eligibility Criteria
Inclusion
- Monobacterial methicillin susceptible Staphylococcus aureus (MSSa) bacteremia
- In the cefazolin group : Cefazolin injectable prescription in the week before or the week after MSSa bacteremia
- In the ASPs group :ASPs injectable prescription (flucloxacillin, floxacillin, cloxacillin, oxacillin, nafcillin and dicloxacillin) in the week before or the week after MSSa bacteremia
Exclusion
- In the cefazolin group : ASP injectable prescription in the year before or the year after MSSa bacteremia
- In the ASPs group : cefazolin injectable prescription in the year before or the year after MSSa bacteremia
Key Trial Info
Start Date :
January 1 2000
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT07186894
Start Date
January 1 2000
End Date
September 1 2026
Last Update
September 22 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.